Tandem Diabetes Care Inc (NASDAQ: TNDM)

Tandem Diabetes Care, Inc. is a global leader in insulin delivery and diabetes technology. The company designs, develops, and commercializes advanced solutions that reduce the burden of diabetes management for people with insulin dependent diabetes. It serves nearly 500,000 individuals in more than 25 countries worldwide. Its portfolio includes durable insulin pumps, single use supplies, and software platforms that offer flexibility and choice in intelligent insulin delivery.

The company generates revenue primarily from the sale of its insulin pump systems, including the t:slim X2 and Mobi platforms. It also sells single use cartridges and infusion sets that are required for pump operation and are replaced every few days. Additionally, Tandem offers software and data management products such as Tandem Source, Tandem Device Updater, and Sugarmate, which are provided to patients, caregivers, and healthcare providers. Revenue is derived from direct sales in the United States and Canada and through independent distributors in other international markets. Reimbursement from durable medical equipment and pharmacy channels in the United States further supports sales.

Tandem Diabetes Care holds a strong position in the global insulin pump market, competing with companies such as Beta Bionics, Insulet, Medtronic, mylife (formerly Ypsomed), and Sequel. Its competitive advantages include the Control IQ+ advanced hybrid closed loop algorithm, compatibility with multiple continuous glucose monitoring sensors, and a user friendly device design. The company benefits from a robust intellectual property portfolio that protects its pump hardware, cartridges, and software innovations. Although the worldwide insulin pump market remains underpenetrated, Tandem leverages its differentiated product lineup to capture share among patients seeking automation and convenience in diabetes care.

Tandem Diabetes Care serves people with insulin dependent diabetes, encompassing both type 1 diabetes patients and type 2 diabetes patients who require intensive insulin therapy. Its customers include individual patients, their caregivers, and healthcare professionals who prescribe and support pump therapy. The company also works with independent distributors and pharmacy partners to reach patients in over 25 countries. No specific customer names are disclosed in the filing.